Last Updated: 18 Sep 2024
Executive Summary
Avalo Therapeutics Inc. (AVTX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer and immune disorders. The company's lead product candidate, AVTX-001, is an anti-CD25 antibody currently in Phase 1b/2a clinical trials for the treatment of hematologic malignancies and solid tumors.
Company Overview
Founded in 2016 and headquartered in Rockville, Maryland
Led by a team of experienced executives from the biotechnology industry
Focused on developing innovative immunotherapies for unmet medical needs
Fundamental Analysis
Revenue for the latest quarter (ending June 2024) was $807,000, a decrease of 0.36% year-over-year
EBITDA for the latest quarter was -$22.05 million
Net loss for the latest quarter was -$20.1 million
Book value per share is -$13.16
EPS for the latest quarter was -$7,126.35
Technical Analysis
The stock price is currently trading at $9.42, within a 52-week range of $3.95 to $52.75
The 50-day moving average is $10.40, while the 200-day moving average is $10.07
The relative strength index (RSI) is at 45.7, indicating a neutral market condition
Short Term Outlook
The company is expected to release clinical data from its Phase 1b/2a trials for AVTX-001 in the second half of 2024
Positive clinical results could drive the stock price higher
The overall market sentiment and macroeconomic factors will also influence the short-term performance of the stock
Long Term Outlook
If AVTX-001 proves to be safe and effective, it could become a valuable treatment option for patients with cancer and immune disorders
The company has a strong pipeline of additional immunotherapies in development
The long-term outlook for Avalo Therapeutics is positive, assuming successful clinical development and regulatory approval of its product candidates
Analyst Recommendations
The analyst consensus rating for AVTX is "Strong Buy"
The average analyst target price is $35
One analyst has a "Strong Buy" rating, while no analysts have "Buy," "Hold," "Sell," or "Strong Sell" ratings
